Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks-- and the track records of the firm behind them -- so individuals can make better investing decisions.

In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 130,000 members, many of whom demonstrate better investing insight than published analysts do.

Enough top-performing CAPS members have recently turned bullish on Forest Labs (NYSE:FRX) to upgrade it from its long-held four-star rank to the highest possible five stars. A total of 449 members have given their opinion on Forest Labs, with many offering analysis and commentary to explain their recent optimism.

Forest Labs has already picked up a couple of FDA approvals so far this year. With partner Cypress Bioscience, it had the fibromyalgia drug Savella approved in January, to compete with Pfizer's (NYSE:PFE) Lyrica and Eli Lilly's (NYSE:LLY) Cymbalta. Also, its depression treatment Lexapro -- a rival for Pfizer's Zoloft and GlaxoSmithKline's (NYSE:GSK) Paxil -- was recently approved for adolescents, only the second drug to earn that distinction. (Eli Lilly's Prozac is the other one.) Lexapro is already marketed to adults, with annual sales of more than $2 billion.

Like sanofi-aventis (NYSE:SNY) and Bristol-Myers Squibb (NYSE:BMY), Forest faces patent expirations on Lexapro and Namenda in a few years, which could bring generic competition. Companies such as Teva Pharmaceuticals (NASDAQ:TEVA) have already taken a legal shot at Lexapro. Forest is counting on Savella and other new drugs to help replace that revenue, and its management sees potential in the drugmaker's late-stage pipeline. It also has plenty of resources to help stave off an impending revenue drop, with more than $2 billion in cash and short-term investments and no debt at the end of 2008. And with solid free cash flow continually adding to the pile, many investors see plenty of options available for the drugmaker.

To see what the very best CAPS analysts are saying now about Forest Labs -- and what other winning stocks they're picking -- head on over to CAPS and have a look. Unlike analysts' opinions, which are usually reserved only for paying clients, the community research and resources in CAPS are totally free.

More Foolishness:

Motley Fool Inside Value looks for solid companies whose shares have been beaten down to dirt cheap levels. Discover the analyst team's picks for the best of Wall Street's bargain bin with a free 30-day trial.

Fool contributor Dave Mock recently upgraded his medicine cabinet with chewable vitamins and grape-flavored toothpaste. He owns shares of Pfizer, which is also an Inside Value selection. GlaxoSmithKline is an Income Investor recommendation. The Fool's disclosure policy will let you pick a toy from the prize basket if you're a good patient.